AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 50 filers reported holding AVROBIO INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $504,989 | +85.9% | 327,915 | +14.7% | 0.00% | 0.0% |
| Q2 2023 | $271,597 | -18.4% | 285,861 | -14.2% | 0.00% | 0.0% |
| Q1 2023 | $332,998 | +47.0% | 332,998 | +4.8% | 0.00% | 0.0% |
| Q4 2022 | $226,596 | -10.1% | 317,851 | -19.0% | 0.00% | 0.0% |
| Q3 2022 | $252,000 | -42.2% | 392,624 | -17.1% | 0.00% | 0.0% |
| Q2 2022 | $436,000 | -50.9% | 473,644 | -29.6% | 0.00% | -66.7% |
| Q1 2022 | $888,000 | -51.1% | 672,433 | +42.5% | 0.00% | -25.0% |
| Q4 2021 | $1,817,000 | -0.5% | 471,934 | +44.2% | 0.00% | 0.0% |
| Q3 2021 | $1,826,000 | +69.1% | 327,248 | +169.5% | 0.00% | +100.0% |
| Q2 2021 | $1,080,000 | -29.0% | 121,448 | +1.3% | 0.00% | -50.0% |
| Q1 2021 | $1,521,000 | +16.8% | 119,871 | +28.4% | 0.00% | 0.0% |
| Q4 2020 | $1,302,000 | +670.4% | 93,380 | +621.5% | 0.00% | +300.0% |
| Q3 2020 | $169,000 | -85.3% | 12,942 | -80.4% | 0.00% | -83.3% |
| Q2 2020 | $1,149,000 | +52.2% | 65,863 | +75.6% | 0.01% | +200.0% |
| Q4 2019 | $755,000 | – | 37,501 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |